Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

844
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
844
Cancer Prevention02:59

Cancer Prevention

8.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.7K
Cancer Prevention02:59

Cancer Prevention

3.1K
3.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

565
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
565

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-depth behavioral characterization of a rat model of Schaaf-Yang syndrome.

Scientific reports·2025
Same author

Online Training to Increase Genetic and Risk Literacy in Physicians Counseling Breast and Ovarian Cancer Patients for Genetic Testing.

Breast care (Basel, Switzerland)·2025
Same author

The Natural Course of Bosch-Boonstra-Schaaf Optic Atrophy Syndrome.

Clinical genetics·2025
Same author

Calculating Future 10-Year Breast Cancer Risks in Risk-Adapted Surveillance: A Method Comparison and Application in Clinical Practice.

Cancer prevention research (Philadelphia, Pa.)·2024
Same author

Genetic Determined Iron Starvation Signature in Friedreich's Ataxia.

Movement disorders : official journal of the Movement Disorder Society·2024
Same author

Dopamine‑iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease.

Neurobiology of disease·2024

Related Experiment Video

Updated: Apr 12, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K

Breast cancer risks and risk prediction models.

Christoph Engel1, Christine Fischer2

  • 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany.

Breast Care (Basel, Switzerland)
|May 12, 2015
PubMed
Summary

Individuals with BRCA1/2 gene mutations face higher breast and ovarian cancer risks. Precise risk assessment is crucial for personalized management, utilizing empirical data and predictive models.

Keywords:
Breast cancerHereditary cancer riskOvarian cancerRisk prediction models

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K

Area of Science:

  • Genetics
  • Oncology
  • Epidemiology

Background:

  • BRCA1/2 mutations significantly elevate risks for breast and ovarian cancers.
  • Accurate cancer risk assessment is vital for personalized management of carriers and high-risk individuals.

Purpose of the Study:

  • To provide an overview of empirical cancer risks associated with BRCA1/2 mutations.
  • To describe current risk prediction models for individual risk assessment in clinical practice.

Main Methods:

  • Literature review of empirical cancer risks for BRCA1/2 mutation carriers.
  • Description of risk prediction models incorporating family history, genetics, and other risk factors.

Main Results:

  • Reported breast cancer risks: BRCA1 (40-87%), BRCA2 (18-88%).
  • Reported ovarian cancer risks: BRCA1 (22-65%), BRCA2 (10-35%).
  • High contralateral breast cancer risk noted: BRCA1 (27% 10-yr), BRCA2 (19% 10-yr).

Conclusions:

  • Cancer risk estimates exhibit considerable variability across studies.
  • Further validation of risk prediction models using prospective data is essential.
  • Standardized documentation during clinical management is recommended for data collection.